GlassScriptPhysician profile
Neil Kalbag
NPI 1861806002
$2,671.93
in general payments reported to CMS, 2019-2025
20 companies · $765 in 2025
The $765 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2021: $64.17 · 2022: $234 · 2023: $459 · 2024: $705 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $529.84 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $294.54 | 2019-2025 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $224.00 | 2019 | |
| Alcon Vision LLC | $208.69 | 2023-2025 | Rocklatan, Eysuvis, Tryptyr |
| Abbvie INC. | $204.03 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $196.83 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $193.89 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $168.09 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $138.23 | 2021-2025 | |
| Astellas Pharma US INC | $129.44 | 2023-2025 | Izervay |
| Dompe US, INC. | $78.35 | 2025 | Oxervate |
| Alimera Sciences, INC. | $71.25 | 2021-2023 | Iluvien |
| Novartis Pharmaceuticals Corporation | $44.13 | 2021-2023 | |
| Harrow Eye, LLC | $43.64 | 2024 | Vevye |
| Coherus Oncology, INC. | $33.07 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $26.21 | 2025 | Hylenex Recombinant |
| Apellis Pharmaceuticals, INC. | $24.18 | 2024 | Syfovre |
| Eyepoint US, INC. | $24.12 | 2023 | |
| Thea Pharma INC. | $21.20 | 2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $18.20 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Kalbag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.